Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression

被引:217
作者
Ylisastigui, L
Archin, NM
Lehrman, G
Bosch, RJ
Margolis, DM
机构
[1] Univ Texas, SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA
[2] N Texas Vet Hlth Care Syst, Dallas, TX USA
[3] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
关键词
latency; histone deacetylase; resting CD4 T cells;
D O I
10.1097/00002030-200405210-00003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Histone deacetylase (HDAC), a host mediator of gene repression, inhibits HIV gene expression and virus production and may contribute to quiescence of HIV within resting CD4 T cells. Objectives: To test the ability of valproic acid (VPA), an inhibitor of HDAC in clinical use, to induce expression of HIV from resting CD4 T cells. Methods: Chromatin immunoprecipitation measured the capability of VPA to deacetylate the HIV promoter, a remodeling of chromatin linked to gene expression. The effect of VPA on resting CD4 T cell phenotype was measured by flow cytometric analysis, and its effect on de novo HIV infection of peripheral blood mononuclear cells was measured ex vivo. Outgrowth of HIV from resting CD4 T cells of aviremic, HIV-infected donors treated with highly active antiretroviral therapy was compared in limiting-dilution cultures after mitogen stimulation or exposure to VPA. Results: VPA induced acetylation at the integrated HIV proviral promoter, but CD4 cells exposed to VPA did not become activated or more permissive for de novo HIV infection. VPA induced outgrowth of HIV from the resting CD4 cells of aviremic patients at concentrations achievable in vivo as frequently as did mitogen stimulation. Conclusions: With advances in antiretroviral therapy, HIV infection might be cleared by intensive time-limited treatment coupled with practical strategies that disrupt latency without enhancing new infection. HDAC inhibitors are capable of inducing expression of quiescent provirus, without fully activating cells or enhancing de novo infection, and may be useful in future clinical protocols that seek to eradicate HIV infection. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:1101 / 1108
页数:8
相关论文
共 47 条
  • [1] Activation of integrated provirus requires histone acetyltransferase - p300 AND P/CAF are coactivators for HIV-1 Tat
    Benkirane, M
    Chun, RF
    Xiao, H
    Ogryzko, VV
    Howard, BH
    Nakatani, Y
    Jeang, KT
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (38) : 24898 - 24905
  • [2] Identification of T cell-signaling pathways that stimulate latent HIV in primary cells
    Brooks, DG
    Arlen, PA
    Gao, LY
    Kitchen, CMR
    Zack, JA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (22) : 12955 - 12960
  • [3] Molecular characterization, reactivation, and depletion of latent HIV
    Brooks, DG
    Hamer, DH
    Arlen, PA
    Gao, LY
    Bristol, G
    Kitchen, CMR
    Berger, EA
    Zack, JA
    [J]. IMMUNITY, 2003, 19 (03) : 413 - 423
  • [4] IN-VIVO FATE OF HIV-1-INFECTED T-CELLS - QUANTITATIVE-ANALYSIS OF THE TRANSITION TO STABLE LATENCY
    CHUN, TW
    FINZI, D
    MARGOLICK, J
    CHADWICK, K
    SCHWARTZ, D
    SILICIANO, RF
    [J]. NATURE MEDICINE, 1995, 1 (12) : 1284 - 1290
  • [5] Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection
    Chun, TW
    Carruth, L
    Finzi, D
    Shen, XF
    DiGiuseppe, JA
    Taylor, H
    Hermankova, M
    Chadwick, K
    Margolick, J
    Quinn, TC
    Kuo, YH
    Brookmeyer, R
    Zeiger, MA
    BarditchCrovo, P
    Siliciano, RF
    [J]. NATURE, 1997, 387 (6629) : 183 - 188
  • [6] Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
    Chun, TW
    Stuyver, L
    Mizell, SB
    Ehler, LA
    Mican, JAM
    Baseler, M
    Lloyd, AL
    Nowak, MA
    Fauci, AS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (24) : 13193 - 13197
  • [7] Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
    Chun, TW
    Engel, D
    Mizell, SB
    Hallahan, CW
    Fischette, M
    Park, S
    Davey, RT
    Dybul, M
    Kovacs, JA
    Metcalf, JA
    Mican, JM
    Berrey, MM
    Corey, L
    Lane, HC
    Fauci, AS
    [J]. NATURE MEDICINE, 1999, 5 (06) : 651 - 655
  • [8] Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides
    Coull, JJ
    He, GC
    Melander, C
    Rucker, VC
    Dervan, PB
    Margolis, DM
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (23) : 12349 - 12354
  • [9] The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1
    Coull, JJ
    Romerio, F
    Sun, JM
    Volker, JL
    Galvin, KM
    Davie, JR
    Shi, Y
    Hansen, U
    Margolis, DM
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (15) : 6790 - 6799
  • [10] Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
    Dornadula, G
    Zhang, H
    VanUitert, B
    Stern, J
    Livornese, L
    Ingerman, MJ
    Witek, J
    Kedanis, RJ
    Natkin, J
    DeSimone, J
    Pomerantz, RJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (17): : 1627 - 1632